712 related articles for article (PubMed ID: 21782482)
21. Prognostic factors including Ki-67 and p53 in Bacillus Calmette-Guérin-treated non-muscle-invasive bladder cancer: a prospective study.
Oderda M; Ricceri F; Pisano F; Fiorito C; Gurioli A; Casetta G; Zitella A; Pacchioni D; Gontero P
Urol Int; 2013; 90(2):184-90. PubMed ID: 23328160
[TBL] [Abstract][Full Text] [Related]
22. Prognostic markers of intravesical bacillus Calmette-Guérin therapy for multiple, high-grade, stage T1 bladder cancers.
Lee E; Park I; Lee C
Int J Urol; 1997 Nov; 4(6):552-6. PubMed ID: 9477182
[TBL] [Abstract][Full Text] [Related]
23. Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign.
Li R; Metcalfe MJ; Tabayoyong WB; Guo CC; Nogueras González GM; Navai N; Grossman HB; Dinney CP; Kamat AM
Eur Urol Oncol; 2019 May; 2(3):286-293. PubMed ID: 31200843
[TBL] [Abstract][Full Text] [Related]
24. Prognostic value of p53 overexpression in T1G3 bladder tumors treated with bacillus Calmette-Guérin therapy.
Peyromaure M; Weibing S; Sebe P; Verpillat P; Toublanc M; Dauge MC; Boccon-Gibod L; Ravery V
Urology; 2002 Mar; 59(3):409-13. PubMed ID: 11880082
[TBL] [Abstract][Full Text] [Related]
25. Twelve-year follow up of a randomized prospective trial comparing bacillus Calmette-Guerin and epirubicin as adjuvant therapy in superficial bladder cancer.
Cheng CW; Chan SF; Chan LW; Chan CK; Ng CF; Cheung HY; Chan SY; Wong WS; Lai FM; To KF; Li ML
Int J Urol; 2005 May; 12(5):449-55. PubMed ID: 15948743
[TBL] [Abstract][Full Text] [Related]
26. Adjuvant intravesical instillation for primary T1G3 bladder cancer: BCG versus MMC in Korea.
Cho IC; Kim EK; Joung JY; Seo HK; Chung J; Park WS; Lee KH
Anticancer Res; 2012 Apr; 32(4):1493-8. PubMed ID: 22493392
[TBL] [Abstract][Full Text] [Related]
27. Prognostic value of Bcl-2 and Bax tumor cell expression in patients with non muscle-invasive bladder cancer receiving bacillus Calmette-Guerin immunotherapy.
Ajili F; Kaabi B; Darouiche A; Tounsi H; Kourda N; Chebil M; Manai M; Boubaker S
Ultrastruct Pathol; 2012 Feb; 36(1):31-9. PubMed ID: 22292735
[TBL] [Abstract][Full Text] [Related]
28. Pretreatment p53 nuclear overexpression as a prognostic marker in superficial bladder cancer treated with Bacillus Calmette-Guérin (BCG).
Saint F; Le Frere Belda MA; Quintela R; Hoznek A; Patard JJ; Bellot J; Popov Z; Zafrani ES; Abbou CC; Chopin DK; de Medina SG
Eur Urol; 2004 Apr; 45(4):475-82. PubMed ID: 15041112
[TBL] [Abstract][Full Text] [Related]
29. p53 status does not predict initial clinical response to bacillus Calmette-Guerin intravesical therapy in T1 bladder tumors.
Pages F; Flam TA; Vieillefond A; Molinie V; Abeille X; Lazar V; Bressac-de Paillerets B; Mosseri V; Zerbib M; Fridman WH; Debré B; Thiounn N
J Urol; 1998 Mar; 159(3):1079-84. PubMed ID: 9474235
[TBL] [Abstract][Full Text] [Related]
30. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin.
Thalmann GN; Sermier A; Rentsch C; Möhrle K; Cecchini MG; Studer UE
J Urol; 2000 Dec; 164(6):2129-33. PubMed ID: 11061941
[TBL] [Abstract][Full Text] [Related]
31. Bacillus Calmette-Guérin therapy in stage Ta/T1 bladder cancer: prognostic factors for time to recurrence and progression.
Andius P; Holmäng S
BJU Int; 2004 May; 93(7):980-4. PubMed ID: 15142147
[TBL] [Abstract][Full Text] [Related]
32. Long-term efficacy of intravesical bacillus Calmette-Guerin for carcinoma in situ: relationship of progression to histological response and p53 nuclear accumulation.
Ovesen H; Horn T; Steven K
J Urol; 1997 May; 157(5):1655-9. PubMed ID: 9112499
[TBL] [Abstract][Full Text] [Related]
33. An analysis of the effect of statin use on the efficacy of bacillus calmette-guerin treatment for transitional cell carcinoma of the bladder.
Berglund RK; Savage CJ; Vora KC; Kurta JM; Cronin AM
J Urol; 2008 Oct; 180(4):1297-300; discussion 1300. PubMed ID: 18707737
[TBL] [Abstract][Full Text] [Related]
34. Long-term follow-up of T1 high-grade bladder cancer after intravesical bacille Calmette-Guérin treatment.
Kakiashvili DM; van Rhijn BW; Trottier G; Jewett MA; Fleshner NE; Finelli A; Azuero J; Bangma CH; Vajpeyi R; Alkhateeb S; Hanna S; Kostynsky A; Kuk C; Van Der Kwast TH; Zlotta AR
BJU Int; 2011 Feb; 107(4):540-6. PubMed ID: 21276177
[TBL] [Abstract][Full Text] [Related]
35. Prognostic value of histopathological tumour growth patterns at the invasion front of T1G3 urothelial carcinoma of the bladder.
Denzinger S; Burger M; Fritsche HM; Bertz S; Hofstädter F; Wieland WF; Hartmann A; Otto W
Scand J Urol Nephrol; 2009; 43(4):282-7. PubMed ID: 19382004
[TBL] [Abstract][Full Text] [Related]
36. [Establishment of the prognostic evaluation system of T1G3 bladder urothelial cancer].
Li XD; Sun G; Liu XQ
Zhonghua Wai Ke Za Zhi; 2013 Aug; 51(8):741-5. PubMed ID: 24252684
[TBL] [Abstract][Full Text] [Related]
37. Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer.
Bertz S; Otto W; Denzinger S; Wieland WF; Burger M; Stöhr R; Link S; Hofstädter F; Hartmann A
Eur Urol; 2014 Jan; 65(1):218-26. PubMed ID: 22633802
[TBL] [Abstract][Full Text] [Related]
38. Predictive value of p53 and pRb expression in superficial bladder cancer patients treated with BCG and interferon-alpha.
Esuvaranathan K; Chiong E; Thamboo TP; Chan YH; Kamaraj R; Mahendran R; Teh M
Cancer; 2007 Mar; 109(6):1097-105. PubMed ID: 17311305
[TBL] [Abstract][Full Text] [Related]
39. The expression level of ligands for natural killer cell receptors predicts response to bacillus Calmette-Guerin therapy: a pilot study.
Yutkin V; Pode D; Pikarsky E; Mandelboim O
J Urol; 2007 Dec; 178(6):2660-4. PubMed ID: 17945285
[TBL] [Abstract][Full Text] [Related]
40. Overexpression of p53 protein in a high-risk population of patients with superficial bladder cancer before and after bacillus Calmette-Guérin therapy: correlation to clinical outcome.
Lacombe L; Dalbagni G; Zhang ZF; Cordon-Cardo C; Fair WR; Herr HW; Reuter VE
J Clin Oncol; 1996 Oct; 14(10):2646-52. PubMed ID: 8874323
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]